472 related articles for article (PubMed ID: 3881561)
21. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
22. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
Ejlertsen B; Jensen MB; Elversang J; Rasmussen BB; Andersson M; Andersen J; Nielsen DL; Cold S; Mouridsen HT
Eur J Cancer; 2013 Sep; 49(14):2986-94. PubMed ID: 23756360
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.
International Breast Cancer Study Group
J Clin Oncol; 1997 Apr; 15(4):1385-94. PubMed ID: 9193330
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
Kaufmann M; Jonat W; Abel U; Hilfrich J; Caffier H; Kreienberg R; Trams G; Brunnert K; Schermann J; Kleine W
J Clin Oncol; 1993 Mar; 11(3):454-60. PubMed ID: 8445420
[TBL] [Abstract][Full Text] [Related]
25. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.
Falkson G; Gelman RS; Pandya KJ; Osborne CK; Tormey D; Cummings FJ; Sledge GW; Abeloff MD
J Clin Oncol; 1998 May; 16(5):1669-76. PubMed ID: 9586877
[TBL] [Abstract][Full Text] [Related]
26. Maintenance tamoxifen after induction postoperative chemotherapy in node-positive breast cancer patients: the Eastern Cooperative Oncology Group Trials.
Tormey DC; Gray R; Falkson HC; Gilchrist K; Abeloff MD; Falkson G
Recent Results Cancer Res; 1993; 127():185-96. PubMed ID: 8502815
[No Abstract] [Full Text] [Related]
27. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
Fisher B; Dignam J; Wolmark N; DeCillis A; Emir B; Wickerham DL; Bryant J; Dimitrov NV; Abramson N; Atkins JN; Shibata H; Deschenes L; Margolese RG
J Natl Cancer Inst; 1997 Nov; 89(22):1673-82. PubMed ID: 9390536
[TBL] [Abstract][Full Text] [Related]
28. Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer.
Pearson OH; Hubay CA; Gordon NH; Marshall JS; Crowe JP; Arafah BM; McGuire W
Cancer; 1989 Nov; 64(9):1819-23. PubMed ID: 2790695
[TBL] [Abstract][Full Text] [Related]
29. Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.
Jakesz R; Hausmaninger H; Haider K; Kubista E; Samonigg H; Gnant M; Manfreda D; Tschurtschenthaler G; Kolb R; Stierer M; Fridrik M; Mlineritsch B; Steindorfer P; Mittlböck M; Steger G
J Clin Oncol; 1999 Jun; 17(6):1701-9. PubMed ID: 10561206
[TBL] [Abstract][Full Text] [Related]
30. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.
Tormey DC; Gray R; Falkson HC
J Natl Cancer Inst; 1996 Dec; 88(24):1828-33. PubMed ID: 8961972
[TBL] [Abstract][Full Text] [Related]
31. Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients.
International Breast Cancer Study Group
Ann Oncol; 1990; 1(1):30-5. PubMed ID: 2078483
[TBL] [Abstract][Full Text] [Related]
32. Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer.
Ingle JN; Everson LK; Wieand HS; Cullinan SA; Wold LE; Hagen JB; Martin JK; Krook JE; Fitzgibbons RG; Foley JF
Cancer; 1989 Apr; 63(7):1257-64. PubMed ID: 2646004
[TBL] [Abstract][Full Text] [Related]
33. Ludwig Breast Cancer trial LBCS III: chemo- and endocrine adjuvant treatment in postmenopausal patients.
Gelber RD
Recent Results Cancer Res; 1984; 96():102-9. PubMed ID: 6396763
[No Abstract] [Full Text] [Related]
34. Randomized cooperative study of perioperative chemotherapy in breast cancer.
Sertoli MR; Bruzzi P; Pronzato P; Queirolo P; Amoroso D; Del Mastro L; Venturini M; Vigani A; Bertelli G; Campora E
J Clin Oncol; 1995 Nov; 13(11):2712-21. PubMed ID: 7595729
[TBL] [Abstract][Full Text] [Related]
35. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
36. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial.
Boccardo F; Rubagotti A; Amoroso D; Sismondi P; Genta F; Nenci I; Piffanelli A; Farris A; Castagnetta L; Traina A
Eur J Cancer; 1992; 28(2-3):673-80. PubMed ID: 1591091
[TBL] [Abstract][Full Text] [Related]
38. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 Sep; 352(9132):930-42. PubMed ID: 9752815
[TBL] [Abstract][Full Text] [Related]
39. Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors.
Cummings FJ; Gelman R; Horton J
J Clin Oncol; 1985 Jul; 3(7):932-40. PubMed ID: 3894587
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant treatment in operable breast cancer.
Goldhirsch A
J Steroid Biochem; 1985 Dec; 23(6B):1155-60. PubMed ID: 3912622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
